Soluble B7-H1

• US 20090176317A1
• Filed: 10/20/2008
• Published: 07/09/2009
• Est. Priority Date: 04/20/2006
• Status: Abandoned Application

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Inman, Brant A., Baro, Xavier Frigola, Kwon, Eugene D., Dong, Haidong
• Application Number:
  US12/254,478
• Publication Number:
  US 20090176317A1
• Time in Patent Office: Days
• US Class Current: 436/501
• CPC Class Codes: G01N 2333/70532 B7 molecules, e.g. CD80, CD86
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids

Abstract

This document features methods of evaluating mammals by assessing expression of B7-H4 in the vasculature.

Claims

1. A method of evaluating a mammal, said method comprising (a) providing a body fluid from said mammal, and (b) detecting the presence or absence of B7-H1 in said body fluid.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein B7-H1 is detected immunologically.

4. The method of claim 1, wherein B7-H1 is detected using a monoclonal antibody.

5. The method of claim 1, wherein B7-H1 is detected using a capture antibody and a reporter antibody, wherein said reporter antibody comprises a label.

6. The method of claim 1, wherein said body fluid is selected from the group consisting of blood, plasma, serum, urine, cerebrospinal fluid, sputum, tears, and saliva.

7. The method of claim 6, wherein said body fluid is serum.

8. The method of claim 1, wherein said mammal is suspected of having a cancer.

9. The method of claim 8, wherein said cancer is renal cell carcinoma.

10. The method of claim 1, wherein the presence of B7-H1 in said body fluid indicates the presence of a cancer in said mammal.

11. The method of claim 10, wherein the presence of B7-H1 in said body fluid indicates said mammal is more likely to die of said cancer than if B7-H1 is absent.

12. A method of detecting B7-H1 in a body fluid, said method comprising:

(a) providing a solid substrate, said solid substrate coated with capture antibodies having binding affinity for soluble B7-H1;

(b) contacting said body fluid with said solid substrate under conditions in which soluble B7-H1, if present, becomes bound to said solid substrate to form a first reacted solid substrate;

(c) contacting said first reacted solid substrate with a reporter antibody having binding affinity for soluble B7-H1 to form a second reacted solid substrate; and

(d) detecting the presence or absence of said reporter antibody on said second reacted solid substrate, wherein the presence of reporter antibody indicates that soluble B7-H1 is present in said body fluid.

13. The method of claim 12, wherein said reporter antibody comprises a label selected from the group consisting of a radioisotope, a fluorophore, a luminescent moiety, biotin, and an enzyme.

14. The method of claim 12, wherein detecting the presence or absence of said reporter antibody comprises contacting said second reacted solid substrate with a secondary antibody having binding affinity for said reporter antibody, wherein said secondary antibody comprises a label.

15. The method of claim 12, wherein detecting the presence or absence of said reporter antibody comprises contacting said second reacted solid substrate with a reagent having binding affinity for said reporter antibody, wherein said reagent comprises a label.

16. The method of claim 12, wherein said solid substrate is a bead or a microtiter plate.

17. A method for determining whether a mammal has cancer, said method comprising (a) determining whether or not a mammal has a body fluid containing an elevated level of a B7-H1 polypeptide, and (b) classifying said mammal as having cancer if said mammal has said elevated level or classifying said mammal as not having cancer if said mammal does not have said elevated level.

18. The method of claim 17, wherein said mammal is a human.

19. The method of claim 17, wherein said body fluid is blood, serum, plasma, or urine.

20. The method of claim 17, wherein said cancer is renal cell carcinoma.